Key result
Morphine use for pain control in acute coronary syndrome was associated with an increased risk of in-hospital recurrent MI (OR 1.30; 95% CI 1.18-1.43; p<0.00001).
Why the study?
Studies have questioned the safety of morphine in ACS due to concerns regarding interaction with and reduced efficacy of antiplatelet agents.
Does morphine use increase the risk of adverse clinical outcomes in patients with acute coronary syndrome?
Meta-Analysis (n=64,323)
Does morphine use increase the risk of adverse clinical outcomes in patients with acute coronary syndrome?
Odds Ratio: 1.3 (95% CI 1.18–1.43)
p-value: p=< 0.00001
Morphine use for pain control in acute coronary syndrome is associated with a significantly increased risk of in-hospital recurrent myocardial infarction, suggesting caution with its routine use.
Morphine in ACS was associated with higher recurrent MI risk; leaves open whether RCTs will confirm causality before practice change.
BACKGROUND: Morphine is widely used for pain control in patients with acute coronary syndrome (ACS). Several studies have questioned the safety of morphine in this setting with a concern of interaction with and reduced efficacy of antiplatelet agents. OBJECTIVE: This study aims to systematically review the safety of morphine use in ACS. METHODS: MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials were queried from inception through April 2018. Studies comparing morphine to nonmorphine use in ACS were included. Study endpoints included: in-hospital myocardial infarction (MI), all-cause mortality, stroke, major bleeding, minor bleeding and dyspnoea. RESULTS: A total of 64 323 patients with ACS were included from eight studies, seven of which were observational studies and one was a randomised controlled trial. The use of morphine was associated with increased risk of in-hospital recurrent MI (OR 1.30, 95% CI 1.18 to 1.43, p < 0.00001). There was, however, no significant difference in terms of all-cause mortality (OR 0.87, 95% CI 0.62 to 1.22, p = 0.44), stroke (OR 0.81, 95% CI 0.39 to 1.66, p = 0.57), major bleeding (OR 0.49, 95% CI 0.24 to 1.00, p = 0.05), minor bleeding (OR 0.98, 95% CI 0.41 to 2.34, p = 0.97), or dyspnoea (OR 0.55, 95% CI 0.16 to 1.83, p = 0.33). CONCLUSION: The use of morphine for pain control in ACS was associated with an increased risk of in-hospital recurrent MI. Randomised clinical trials are needed to further investigate the safety of morphine in ACS.
No takes yet. Share an insight, caveat, or question.
Ghadban et al. (2019) conducted a meta-analysis in Acute coronary syndrome (n=64,323). Morphine vs. Nonmorphine use was evaluated on In-hospital recurrent MI (OR 1.30, 95% CI 1.18 to 1.43, p=< 0.00001). Morphine use for pain control in acute coronary syndrome was associated with an increased risk of in-hospital recurrent MI (OR 1.30; 95% CI 1.18-1.43; p<0.00001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: